ALPINE IMMUNE SCIENCES, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Amortization of premium/discount on investments
Depreciation expense
Non-cash interest expense
Realized gain on investments
Loss on sale of property and equipment
Loss on sale of intangible asset
Bargain purchase gain
Deferred income tax
Changes in operating assets and liabilities:
Accounts receivable
Prepaid expenses and other current assets
Operating lease, right-of-use asset
Accounts payable and accrued liabilities
Deferred revenue
Operating lease liability

Net cash used in operating activities
Investing activities
Purchases of property and equipment
Proceeds from sale of intangible asset
Purchase of investments
Maturities of investments
Proceeds from the sale of investments
Cash and cash equivalents acquired in connection with merger
Net cash used in investing activities

Financing activities
Proceeds from sale of common stock and warrants, net of offering costs
Horizon
Total proceeds from sale of common stock and warrants, net of offering costs
Proceeds from borrowings, net of issuance costs
Proceeds from issuance of common stock to Amgen
Proceeds from exercise of stock options, net of taxes paid on vested RSUs
Proceeds from exercise of warrants
Repayment of debt
Net cash provided by financing activities
Effect of exchange rate on cash and cash equivalents
Net increase (decrease) in cash and cash equivalents and restricted cash
Cash and cash equivalents and restricted cash, beginning of period
Cash and cash equivalents and restricted cash, end of period
Supplemental Information
Recognition of right-of-use asset
Cash paid for income taxes
Cash paid for interest
Convertible preferred stock exchanged for common stock
Discount in connection with issuance of debt

Comments